Magic mushroom therapy targets despair in advanced cancer patients
NCT ID NCT06818994
First seen Mar 20, 2026 · Last updated May 24, 2026 · Updated 6 times
Summary
This early-stage study tests whether psilocybin (the active ingredient in magic mushrooms) combined with talk therapy can safely reduce feelings of hopelessness and loss of meaning in people with advanced cancer. Fifteen adults aged 18-70 with stage 3 or 4 cancer and high demoralization will receive one 25 mg dose of psilocybin along with six therapy sessions. The main goals are to see if the treatment is safe and if it lowers demoralization scores.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEMORALIZATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Queen's University
RECRUITINGKingston, Ontario, K7L 3N6, Canada
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.